Hainan Nuoen Biotechnology

Hainan Nuoen Biotechnology is a clinical-stage biopharmaceutical company headquartered in Haikou, China, specializing in the development of next-generation cell therapies. The company leverages its proprietary N-CAR platform to engineer advanced CAR-T and CAR-NK cell products designed to treat both hematological malignancies and challenging solid tumors. Its pipeline features multi-antigen targeting strategies, such as CD19/CD22 bispecific CAR-T cells, and off-the-shelf CAR-NK therapies targeting Mesothelin and Glypican-3. Nuoen is a key player in the burgeoning life sciences sector of the Hainan Free Trade Port, focusing on accelerating the clinical translation of immunotherapy innovations.